Source: Eur Respir J 2015; 46: 303-306
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hassoun Paul M.. Inflammation in chronic thromboembolic pulmonary hypertension: accomplice or bystander in altered angiogenesis?. Eur Respir J 2015; 46: 303-306

Member's Comments

No comment yet.

Related content which might interest you: Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2015; 46: 431-443 Year: 2015 Microvascular disease in chronic thromboembolic pulmonary hypertension: the story continues Source: Eur Respir J 2014; 44: 1121-1122 Year: 2014 How does inflammation contribute to pulmonary hypertension? Source: Eur Respir J, 51 (1) 1702403; 10.1183/13993003.02403-2017 Year: 2018 Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2014; 44: 842-845 Year: 2014 Chronic thromboembolic pulmonary hypertension at the crossroad Source: Eur Respir J 2014; 43: 1230-1232 Year: 2014 Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature Source: Eur Respir J 2014; 44: 1275-1288 Year: 2014 Chronic thromboembolic pulmonary hypertension and splenectomy: Is there a link? Source: Eur Respir J 2003; 22: Suppl. 45, 218s Year: 2003 Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 C reactive protein level in pulmonary embolism. A marker of inflammatory processes in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2007; 30: Suppl. 51, 602s Year: 2007 Chronic thromboembolic pulmonary hypertension: role of medical therapy Source: Eur Respir J 2013; 41: 985-990 Year: 2013 Pulmonary arterial hypertension: an autoimmune disease? Source: Eur Respir J 2005; 26: 986-988 Year: 2005 The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (3) 1801805; 10.1183/13993003.01805-2018 Year: 2019 ERS statement on chronic thromboembolic pulmonary hypertension Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension Year: 2021 Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Angiogenesis in chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012 Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding Source: Eur Respir J 2013; 41: 462-468 Year: 2013 Inflammation in pulmonary arterial hypertension: is it time to quell the fire? Source: Eur Respir J 2014; 43: 685-688 Year: 2014 Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010 Crucial role of thrombin-activated fibrinolysis inhibitor in the pathogenesis of chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Dysfunctional endothelial cells in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017